SEO URLwww.firestrike.ai/deals/rapt-therapeutics-gsk-acquisition-2026-2

acquisitionAnnounced · Jan 21, 2026biopharmaceuticalSource · CredibleArticle · Factual

RAPT Therapeutics · GSK

GSK acquires RAPT Therapeutics

David Najork · Founding Software Engineer

Published Apr 29, 2026 · Updated Apr 29, 2026 · 1 min read

ShareX LinkedIn Email

Deal value

$2.2B

Target

RAPT Therapeutics

NASDAQ:RAPT · South San Francisco, California

Acquirer

GSK

Full Acquisition

Status

Pending

GSK agreed to acquire RAPT Therapeutics. Reported deal value: $2.2B. Status: Pending. Sector: biopharmaceutical. Target headquarters context: South San Francisco, California, United States.

This page summarizes publicly available information about the transaction as of 2026-01-21. Figures and status may change as filings and press coverage update.

Pharmaceutical Executive Daily: GSK $2 Billion Acquisition of RAPT Therapeutics Author Nicholas Jacobus In today Pharmaceutical Executive Daily, GSK moves to strengthen its immunology pipeline with a $2 billion acquisition of RAPT Therapeutics , Atkins launches a new partnership to better understand consumer mindsets around GLP-1 use, and Shionogi agrees to acquire Pfizer remaining stake in ViiV Healthcare

Deal timeline

Announced

Jan 21, 2026 · pharmexec.com

Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.

Sector context

This transaction is classified in biopharmaceutical with a reported deal value of $2.2B. Figures and status may change as sources update.

Sources: pharmexec.com · Primary article · FireStrike proprietary index